IBDEI1JU ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24764,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,24764,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,24765,0)
 ;;=C92.11^^107^1211^50
 ;;^UTILITY(U,$J,358.3,24765,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24765,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,24765,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,24765,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,24766,0)
 ;;=C92.10^^107^1211^51
 ;;^UTILITY(U,$J,358.3,24766,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24766,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,24766,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,24766,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,24767,0)
 ;;=D47.1^^107^1211^52
 ;;^UTILITY(U,$J,358.3,24767,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24767,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,24767,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,24767,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,24768,0)
 ;;=C82.69^^107^1211^53
 ;;^UTILITY(U,$J,358.3,24768,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24768,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,24768,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,24768,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,24769,0)
 ;;=C82.60^^107^1211^54
 ;;^UTILITY(U,$J,358.3,24769,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24769,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,24769,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,24769,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,24770,0)
 ;;=D56.2^^107^1211^55
 ;;^UTILITY(U,$J,358.3,24770,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24770,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,24770,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,24770,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,24771,0)
 ;;=D75.9^^107^1211^56
 ;;^UTILITY(U,$J,358.3,24771,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24771,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,24771,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,24771,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,24772,0)
 ;;=D59.0^^107^1211^59
 ;;^UTILITY(U,$J,358.3,24772,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24772,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,24772,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,24772,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,24773,0)
 ;;=D59.2^^107^1211^60
 ;;^UTILITY(U,$J,358.3,24773,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24773,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,24773,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,24773,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,24774,0)
 ;;=R59.9^^107^1211^63
 ;;^UTILITY(U,$J,358.3,24774,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24774,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,24774,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,24774,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,24775,0)
 ;;=D47.3^^107^1211^64
 ;;^UTILITY(U,$J,358.3,24775,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24775,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,24775,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,24775,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,24776,0)
 ;;=C82.09^^107^1211^65
 ;;^UTILITY(U,$J,358.3,24776,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24776,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
